Format

Send to

Choose Destination
Peptides. 2015 Jul;69:47-55. doi: 10.1016/j.peptides.2015.03.024. Epub 2015 Apr 4.

The anti-diabetic effects of GLP-1-gastrin dual agonist ZP3022 in ZDF rats.

Author information

1
Research and Development, Zealand Pharma A/S, Glostrup, Denmark. Electronic address: jsk@zealandpharma.com.
2
Gubra ApS, Hørsholm, Denmark.
3
The Sanford Project, Children Health Research Center, Sanford Research/USD, Sioux Falls, SD, United States.
4
Research and Development, Zealand Pharma A/S, Glostrup, Denmark.
5
Department of Biomedical Sciences, University of Copenhagen, Denmark.

Abstract

AIMS/HYPOTHESIS:

Combination treatment with exendin-4 and gastrin has proven beneficial in treatment of diabetes and preservation of beta cell mass in diabetic mice. Here, we examined the chronic effects of a GLP-1-gastrin dual agonist ZP3022 on glycemic control and beta cell dysfunction in overtly diabetic Zucker Diabetic Fatty (ZDF) rats.

METHODS:

ZDF rats aged 11 weeks were dosed s.c., b.i.d. for 8 weeks with vehicle, ZP3022, liraglutide, exendin-4, or gastrin-17 with or without exendin-4. Glycemic control was assessed by measurements of HbA1c and blood glucose levels, as well as glucose tolerance during an oral glucose tolerance test (OGTT). Beta cell dynamics were examined by morphometric analyses of beta and alpha cell fractions.

RESULTS:

ZP3022 improved glycemic control as measured by terminal HbA1c levels (6.2±0.12 (high dose) vs. 7.9±0.07% (vehicle), P<0.001), as did all treatments, except gastrin-17 monotherapy. In contrast, only ZP3022, exendin-4 and combination treatment with exendin-4 and gastrin-17 significantly improved glucose tolerance and increased insulin levels during an OGTT. Moreover, only ZP3022 significantly enhanced the beta cell fraction in ZDF rats, a difference of 41%, when compared to the vehicle group (0.31±0.03 vs. 0.22±0.02%, respectively, P<0.05).

CONCLUSION:

These data suggest that ZP3022 may have therapeutic potential in the prevention/delay of beta cell dysfunction in type 2 diabetes.

KEYWORDS:

Dual agonist; Gastrin; Glucagon-like peptide-1; Pancreatic beta cell; Type 2 diabetes; Zucker diabetic fatty rats

PMID:
25849341
DOI:
10.1016/j.peptides.2015.03.024
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center